BioSpace News Archive

Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2021 and provided a corporate update.

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a rapid quantitative tear test for Lacritin, a tear protein that autonomously promotes tearing and is deficient in all forms of Dry Eye Disease.

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense® System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, 2022 in Vienna, Austria.

Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial.

For the first time ever, adults can opt for a clean alternative with the same efficacy as its counterparts in the medicine aisles.

Fresenius Kabi announced today it has introduced two new presentations of Calcium Gluconate in Sodium Chloride Injection in the United States in the company’s proprietary, ready-to-administer freeflex® containers.

LAVA Therapeutics N.V. announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma at the 2022 American Society of Clinical Oncology Annual Meeting taking place in Chicago and virtually June 3-7, 2022.

SOTIO Biotech announced that it will deliver an oral presentation featuring interim safety and efficacy data from the Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, as monotherapy and in combination with pembrolizumabat the upcoming American Society of Clinical Oncology Annual Meeting 2022, taking place in Chicago, Illinois fromJune 3-7, 2022.

Advaxis, Inc. announced that it will present data from the Phase 2 study of ADXS-503 in combination with pembrolizumab in patients with metastatic non-small cell lung cancer and data from the Phase 1 study of ADXS-504 in patients with biochemically recurrent prostate cancer at the American Society of Clinical Oncology Annual Meeting being held virtually, on June 3-7, 2022.

The report offers detailed overview of the market with recent market dynamics and industrial status. The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market.